Please ensure Javascript is enabled for purposes of website accessibility

Why Intellia Therapeutics Stock Is Skyrocketing Today

By Keith Speights - Jun 28, 2021 at 11:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported promising interim trial results for its CRISPR gene-editing candidate.

What happened

Shares of Intellia Therapeutics (NTLA -1.41%) were trading 40.3% higher as of 11:05 a.m. EDT Monday, after the company and its partner, Regeneron (REGN -2.74%), announced encouraging interim results on Saturday from a phase 1 clinical study evaluating NTLA-2001 as a treatment for the rare genetic disease transthyretin (ATTR) amyloidosis.

So what

The biotech stock vaulted so much higher because investors realized the significance of Intellia's update. The interim results for NTLA-2001 were the first clinical data ever that supported the safety and efficacy of in vivo (in the body) CRISPR gene editing in humans.

DNA images with a healthcare professional in the background.

Image source: Getty Images.

Intellia and Regeneron reported that a single dose of NTLA-2001 achieved an 87% mean reduction in serum transthyretin (TTR) protein levels. There was a maximum serum TTR reduction of 96% by day 28. This is highly encouraging since the current standard of care, Alnylam's Onpattro, typically achieves TTR reductions of 80%. Onpattro also requires dosing every three weeks, whereas NTLA-2001 is a one-time treatment.

The safety profile for NTLA-2001 also looked good. Intellia and Regeneron stated that there were no serious adverse events reported as of 28 days after treatment.

There were only six patients covered in the trial's interim data release. Intellia and Regeneron couldn't have asked for better results at this point, though.

Now what

Intellia's next step will be to present additional data from its phase 1 study of NTLA-2001 at a medical or scientific conference later this year. The company also plans to add another cohort to the study in 2021.

However, the importance of the promising safety and efficacy for the experimental CRISPR therapy goes beyond just one indication. Intellia CEO John Leonard said that this milestone "unlocks the door to treating a wide array of other genetic diseases with our modular platform, and we intend to move quickly to advance and expand our pipeline."

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intellia Therapeutics Stock Quote
Intellia Therapeutics
NTLA
$65.60 (-1.41%) $0.94
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$623.90 (-2.74%) $-17.59
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$229.39 (-1.12%) $-2.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.